Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirikizumab in Older Adults with Moderate to Severe Crohn's Disease and Ulcerative Colitis
NCT07059130Phase 4Not yet recruiting
- Sponsor
- Rubix LS
- Start
- Jul 2025
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of mirikizumab in Crohn's disease, ulcerative colitis (UC), sponsored by Rubix LS. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
mirikizumab
03
Conditions
Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07059130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07059130.